The in vitro activities of imipenem alone and in combination with teicoplanin, fosfomycin, and rifampin were tested against clinical isolates of enterococci and staphylococci. In both groups of organisms, the three combinations demonstrated high rates of synergism in both checkerboard ahd time-kill studies.
Imipenem is the first clinically useful member of the carbapenems, a new class of antimicrobial agents that are unique among ,-lactams both for their chemical structure and because of their extraordinarily broad antibacterial spectrum. Since its development from thienamycin as the N-formimidoyl derivative, imipenem has been studied extensively in recent years, and the data available about its in vitro antibacterial activity have been reviewed repeatedly (5, 12, 13, 16) . However, in this series of studies, investigations of its interactions with other antimicrobial agents are relatively limited. Overall, synergism has been demonstrated in combinations of imipenem with aminoglycosides against enterococci (3, 8, 10, 24) and Listeria monocytogenes (8) and less frequently against staphylococci, enteric gram-negative bacteria, and nonfermentative bacteria (7, 11, 14, 18, 19) . Conversely, imipenem has shown antagonistic interactions with other ,-lactam antimicrobial agents against Pseudomonas aeruginosa (1, 4, 25) and Serratia marcescens (17) and with chloramphenicol against Klebsiella pneumoniae (6) .
In this study, enterococcal and staphylococcal strains freshly isolated from clinical material were tested for susceptibility to imipenem, teicoplanin, fosfomycin, and rifampin. Interactions between imipenem and each of the three other antimicrobial agents were then determined both by checkerboard titration and by time-kill curves.
Enterococci were identified as Streptococcus faecalis (71 isolates) or Streptococcus faecium (10 isolates) on the basis of standard criteria. Staphylococci were identified on the basis of lytic activity patterns (23) trays with Mueller-Hinton broth (Difco) as the test medium. Twofold dilutions of each drug, prepared so as to obtain final concentrations ranging from 0.004 to 64 ,ug/ml, were made with a hand-held multidilution device that delivered 150 jLl per well. Inoculum (50 ,ul; density, approximately 107 CFU/ml) was dispensed into each well with an Eppendorf pipette. After 18 h of incubation at 37°C, the MIC was read as the lowest concentration of antimicrobial agent which allowed no visible growth. MBCs were determined by drawing 100-,pl samples from each of the wells showing no growth with an Eppendorf pipette and spreading them across the surface of plates of brain heart infusion agar (Difco) with sterile, bent glass rods. These plates were incubated at 37°C for 48 h. The MBC was read as the lowest concentration of antimicrobial agent which resulted in -0.1% survival in the subculture.
The MICs and MBCs of the four antimicrobial agents are shown in Table 1 . Resistance to teicoplanin (MIC, .8 ,uglml) was not observed, whereas in both enterococci and staphylococci resistance to fosfomycin (MIC, .32 pgIml) was markedly more frequent than was resistance to the other drugs examined. In staphylococci, rifampin was the only drug for which a higher incidence of resistance (MIC, .8 ,ug/ml) clearly correlated with resistance to methicillin. With teicoplanin, fosfomycin, and rifampin, overall MICs and MBCs were in the ranges of values that this and other laboratories reported previously (9, (20) (21) (22) . With imipenemn, MBC-to-MIC ratios from 1 to 4 (most often 2) were found with both coagulase-positive and coagulase-negative staphylococci. Higher ratios (from 1 to 8, most often 4) were observed with both S. faecalis and S. faecium, but differences between killing and inhibitory concentrations were neither as marked nor as consistent as reported in other studies (2, 8) .
In vitro combinations of imipenem with teicoplanin, fosfomycin, and rifampin were assessed by checkerboard titration in 76 strains and by time-kill curves in 46 of these strains for which the MBCs of the four antimicrobial agents were not higher than the respective concentrations achievable in the blood. Checkerboard studies were performed in microtiter trays as described previously (22) . Antimicrobial interactions were defined by calculating fractional inhibitory concentration indices (15) . Fractional inhibitory concentration indices of c0.5 or >4 were interpreted as synergism or antagonism, respectively, and intermediate values were interpreted as indifference. In time-kill studies, log-phase cultures in Mueller-Hinton broth of the organism to be synergistic or antagonistic when the combination caused a studied were diluted with the same medium containing the .2-log reduction or increake, lespectively, in the CFU at 24 appropriate amount of antimicrobial agents. The final bacteh compared with the more effbctive single antimicrobial rial density was 105 to 106 CFU/ml. Both imipenem and the agent. Intermediate results were interpreted as indifferenee. second antimicrobial agent in the combination had final Imipenem reacted favorably against both enterococci and concentrations of one-fourth their MBCs; at least one of the staphylococci ip combinatibn with each of the three other two drugs, at the concentration used, did not affect the antimicrobial agedts at concentrations clinically achievabld growth curve of the test organism. At 0, 4, 8, and 24 h of for all agents. Antagonism Was never encountered, whertas incubation, the viable numbers of organisms were deterhigh rates of synergism were demonstrated with all conmbimined with serial 10-fold dilutions plated on brain heart nations both by checkerboard titration and by time-kill infusion agar. Antimicrobial interactions were interpreted as curves (Table 2) , although in the latter case an inoculum Because of its broad spectrum of activity at levels achievable in the blood, imipenem is usually regarded as an antimicrobial agent to be administered in monotherapy rather than in combination regimens. Therefore, the practical implications of its in vitro interactions with other antimicrobial agents (whether synergistic or antagonistic) may be inconsequential. Nevertheless, the fact that organisms characteristically tolerant or with a special tendency to develop tolerance to cell-wall-active agents (such as enterococci or methicillin-resistant staphylococci, respectively) were inhibited and killed synergistically at high rates by particular combinations of imipenem with other antimicrobial agents, at clinically relevant concentrations, is a noteworthy and potentially useful piece of information.
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